Toxicity of Capecitabine and Oxaliplatin in Colorectal Cancer
Author Information
Author(s): Baird R, Biondo A, Chhaya V, McLachlan J, Karpathakis A, Rahman S, Barbachano Y, Cunningham D, Chau I
Primary Institution: Royal Marsden Hospital, London & Surrey, UK
Hypothesis
Does reducing the dose of capecitabine from 2000 mg/m² to 1700 mg/m² decrease toxicity in colorectal cancer patients?
Conclusion
Reducing the capecitabine dose did not significantly change the rates of gastrointestinal toxicities or hospitalizations.
Supporting Evidence
- 400 patients were analyzed, with 200 receiving each dose of capecitabine.
- No significant differences in severe diarrhoea rates were found between the two doses.
- Neutropenia and liver dysfunction were significantly reduced with the lower dose.
- Hospitalization rates due to toxicities were similar for both doses.
Takeaway
Doctors tried giving a lower dose of a cancer drug to see if it would make patients feel better, but it didn't really help.
Methodology
Retrospective analysis comparing toxicities before and after a dose reduction of capecitabine.
Potential Biases
Potential bias due to the non-randomized nature of the study and reliance on medical records.
Limitations
The study was retrospective and based on routine clinical practice rather than a controlled trial.
Participant Demographics
Median age was 65 years, with 59% male and 41% female participants.
Statistical Information
P-Value
P=0.80 for grades 3 and 4 diarrhoea, P<0.0001 for elevated bilirubin.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website